Teriflunomide is a medicine used to treat multiple sclerosis (MS). It's taken as a pill once a day. It works by slowing down immune cells that attack the brain and spinal cord.
Every report comes from a Lived member, sent anonymously.
Have you tried Aubagio (Teriflunomide) for Relapsing-Remitting Multiple Sclerosis?
Teriflunomide, sold as Aubagio and also available as a generic, is a once-daily pill for adults with relapsing forms of multiple sclerosis (MS). In MS, the immune system attacks myelin, the protective coating around nerves in the brain and spinal cord, which slows or blocks the signals those nerves carry. Teriflunomide is approved for clinically isolated syndrome (a first episode of MS-like symptoms lasting at least a day), relapsing-remitting MS, in which flare-ups called relapses are followed by periods of recovery, and secondary progressive MS that is still active. It is a disease-modifying therapy: a long-term treatment meant to reduce relapses and slow the build-up of damage, not to relieve symptoms from day to day. Among MS treatments it is a moderate-strength option. It reduces relapses compared with no treatment, but in two large head-to-head trials, people given Kesimpta (ofatumumab), a monthly self-injected antibody, had fewer relapses than people taking teriflunomide. People and their neurologists often weigh that difference against the convenience of a daily pill. Teriflunomide is not approved for children and cannot be used during pregnancy.
To multiply, activated immune cells need a fast supply of pyrimidines, chemical building blocks for new genetic material. Teriflunomide blocks an enzyme called dihydroorotate dehydrogenase, which cells use to make pyrimidines from scratch. This dampens the activation of the T cells and B cells involved in MS attacks, and is thought to leave fewer activated immune cells able to reach the brain and spinal cord. Researchers do not know exactly how this translates into fewer relapses. Teriflunomide is also what the body turns leflunomide (Arava), a rheumatoid arthritis medicine, into, which is why the two share many warnings. It leaves the body unusually slowly. It takes about three months of daily doses to reach a steady level, and after the last dose it takes on average eight months, and sometimes up to two years, to fall to a level considered safe for pregnancy, unless it is removed faster on purpose.
Teriflunomide is a tablet taken once a day, with or without food. It comes in 7 mg and 14 mg strengths, and the prescriber chooses which. In the main trials both strengths reduced relapses, but only 14 mg clearly slowed the worsening of disability. Before the first dose, the care team checks liver blood tests, a complete blood count (which measures infection-fighting white cells and platelets), and blood pressure, and screens for latent tuberculosis with a skin or blood test. Women who could become pregnant have a pregnancy test. Treatment is not started during an active infection. For the first six months, a liver test called ALT (alanine aminotransferase, an enzyme that rises in the blood when liver cells are stressed) is repeated at least once a month. Because the drug lingers for so long, a doctor can clear it quickly with an accelerated elimination procedure: 11 days of cholestyramine, a cholesterol-lowering powder, taken three times a day, or activated charcoal powder taken twice a day. This lowers blood levels by more than 98 percent. It is used for a pregnancy or pregnancy plans, for a serious side effect, and sometimes when switching treatments. Because it removes the medicine, MS activity can return if the drug had been working.
The most common side effects in trials were headache, diarrhea, nausea, hair thinning and a rise in liver enzymes on blood tests. Hair thinning affected about 13 percent of people on 14 mg compared with 5 percent on placebo. Some people also notice tingling or joint pain, and blood pressure tends to rise slightly. White blood cell counts drop by about 15 percent on average, which most people do not feel but which can make infections more likely, so fever, chills or body aches are worth reporting. Call the prescriber right away for signs of liver trouble: nausea or vomiting, stomach pain, loss of appetite, unusual tiredness, yellowing of the skin or eyes, or dark urine. The same applies to new or worsening shortness of breath or cough, which can rarely signal lung inflammation, and to fever or rash together with swollen glands, facial swelling, severe muscle pain or unusual bruising. New numbness or tingling in the hands or feet that feels different from usual MS symptoms can be nerve damage from the drug and should be reported, as should skin or mouth ulcers and wounds that heal slowly. Stop the medicine and get emergency help for swelling of the lips, eyes, throat or tongue, or difficulty breathing, which can be a severe allergic reaction. Rash with peeling skin, blisters or mouth sores can be a rare, life-threatening skin reaction and also needs immediate medical care.
Teriflunomide carries the US Food and Drug Administration's strongest warning, a boxed warning, for two risks. The first is serious liver injury, which has occasionally led to liver failure needing a transplant. It is not used in people with severe liver disease, is usually avoided when liver tests are already high, and needs extra care alongside other medicines that can strain the liver. The second is harm to a developing baby. Teriflunomide must not be taken during pregnancy, and women who could become pregnant need effective birth control throughout treatment and afterward, until a blood test confirms the level has fallen low enough. Anyone who becomes pregnant while taking it, or within two years of stopping, should tell the prescriber right away so the drug can be cleared quickly. The drug is also found in semen: men who want to father a child should stop and either complete the elimination procedure or wait for a confirmed low blood level, and otherwise use effective birth control with their partner. Breastfeeding is not recommended during treatment. Teriflunomide is never combined with leflunomide. Live vaccines are not recommended during treatment or for six months after it ends, so it helps to review vaccinations before starting. It changes the levels of several other medicines: it can lower the effect of warfarin, a blood thinner, so INR (the blood clotting test used to adjust warfarin) needs closer checks; rosuvastatin, a cholesterol medicine, should not go above 10 mg a day; it raises hormone levels from some birth control pills; and it can lower levels of tizanidine, a muscle relaxant. Tell the care team about surgery plans or unhealed wounds, and about every other medicine and supplement, especially other immune-suppressing treatments.
Teriflunomide does not make people feel better from week to week. Its value shows up over months to years as fewer relapses and less new damage. In the main two-year trial, people on either dose had about 31 percent fewer relapses per year than people on placebo, and on 14 mg about 20 percent had worsening disability after two years, compared with 27 percent on placebo. Independent reviewers have rated the quality of this evidence as low, and some people continue to have relapses on it. The first six months involve monthly blood tests, with blood pressure and other checks continuing after that. The neurologist judges how well it is working from relapses, examinations and often magnetic resonance imaging (MRI) scans; ongoing activity is a common reason to move to a more effective therapy. People usually take teriflunomide for as long as it controls their MS and they tolerate it. Its long stay in the body shapes every exit: pregnancy plans, side effects or a switch to another treatment usually involve the elimination procedure or a wait with blood tests, so it is worth planning family decisions with the neurologist well ahead of time.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Aubagio (Teriflunomide), what you've noticed, or ask the community a question.